PI3K/AKT/mTOR Signaling-Mediated Neuropeptide VGF in the Hippocampus of Mice Is Involved in the Rapid Onset Antidepressant-Like Effects of GLYX-13
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: VGF (nonacryonimic) and phosphatidylinositol 3-kinase (PI3K)/AKT (also known as protein kinase B, PKB)/mammalian target of rapamycin (mTOR) signaling play pivotal roles in depression. However, whether phosphatidylinositol 3-kinase/AKT/mTOR signaling-mediated VGF participates in rapid-acting antidepressant-like actions of GLYX-13 is unclear. METHODS: Herein, we evaluated the effects of acute treatment of GLYX-13 (0.5, 5, and 10mg/kg, i.p.) in the forced swim test. In addition, we assessed whether the acute treatment with GLYX-13 reverses the depressive-like behaviors induced by chronic unpredictable mild stress. Furthermore, we determined whether the Vgf knockdown in hippocampus of mice blocks the effects of GLYX-13. Moreover, we also demonstrated the effects of intra-hippocampus infusion of LY294002 (10 nmol/side), a specific phosphatidylinositol 3-kinase inhibitor prior to the treatment of GLYX-13 in the forced swim test. Lastly, whether alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and mTOR activation involves in the antidepressant-like effects of GLYX-13 was examined. RESULTS: Our results shown that GLYX-13 dose-dependently reversed the depressive-like behaviors in forced swim test. Additionally, GLYX-13 significantly reversed the downregulation of phosphorylation of AKT, mTOR, and eukaryotic elongation factor 2 as well as VGF induced by chronic unpredictable mild stress in hippocampus. Further, Vgf knockdown in hippocampus of mice significantly blocked the rapid-acting antidepressant-like effects and upregulation on phosphatidylinositol 3-kinase/AKT/mTOR/VGF signaling of GLYX-13. Moreover, intra-hippocampus infusion of LY294002 significantly abolished the antidepressant-like effects and upregulation on phosphatidylinositol 3-kinase/AKT/mTOR/VGF signaling of GLYX-13. Finally, antidepressant-like effects of GLYX-13 required AMPA receptor and mTOR activation, as evidenced by the ability of NBQX and rapamycin to block the effects of GLYX-13, respectively. CONCLUSIONS: Our results suggest that phosphatidylinositol 3-kinase/AKT/mTOR signaling-mediated VGF in hippocampus may be involved in the antidepressant-like effects of GLYX-13.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 10×
“In addition, BDNF-induced TrkB activation stimulates the PI3K/ AKT signaling pathways, which play a principal role in promoting neuronal survival and synaptic plasticity and antidepressant-like actions (Numakawa et al., 2010, 2013), suggesting that VGF may feedback regulate the PI3K/AKT/mTOR signaling in hippocampus o…”
BackgroundInfluentialNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“…effects of ketamine are mediated by molecular alterations to the mTOR, a serine/threonine kinase and key component of the insulin-signaling pathway and then reduces the expression of eEF2, which prevents protein translation of BDNF (Li et al., 2010; Autry et al., 2011; Monteggia et al., 2013).”
BackgroundNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“Notably, to date, all drugs approved as antidepressant medications are either inhibitors of monoamine transporters or monoamine oxidase (Berton and Nestler, 2006) and take 3 to 8 weeks to exert their effects (Wong and Licinio, 2004).”
BackgroundCastrén, E. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1629 · Cited by 563
Zhou, W., Wang, N., Yang, C., Li, X.-M., Zhou, Z.-Q., & Yang, J.-J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.10.005 · Cited by 390 · cited 1×
“Previous studies suggest that the rapid-acting antidepressant-like effects of ketamine are mediated by molecular alterations to the signaling pathway of phosphatidylinositol 3-kinase (PI3K)/AKT (also known as protein kinase B, PKB)/glycogen synthesis kinase 3 (GSK3)/mammalian target of rapamycin (mTOR)/brain derived n…”
BackgroundSelf-citationBurgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine
Monteggia, L. M., Gideons, E., & Kavalali, E. T. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.006 · Cited by 198 · cited 1×
“…effects of ketamine are mediated by molecular alterations to the mTOR, a serine/threonine kinase and key component of the insulin-signaling pathway and then reduces the expression of eEF2, which prevents protein translation of BDNF (Li et al., 2010; Autry et al., 2011; Monteggia et al., 2013).”
BackgroundYang, C., Hu, Y.-M., Zhou, Z.-Q., Zhang, G.-F., & Yang, J.-J. (2013) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.724118 · Cited by 173 · cited 1×
“Previous studies suggest that the rapid-acting antidepressant-like effects of ketamine are mediated by molecular alterations to the signaling pathway of phosphatidylinositol 3-kinase (PI3K)/AKT (also known as protein kinase B, PKB)/glycogen synthesis kinase 3 (GSK3)/mammalian target of rapamycin (mTOR)/brain derived n…”
Background
Cited by
Lepack, A. E., Bang, E., Lee, B., Dwyer, J. M., & Duman, R. S. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.011 · Cited by 174
“…demonstrate that these two drugs also stimulate mTORC1 signaling and produce antidepressant behavioral responses that are dependent on activation of AMPA receptors and mTORC1 (Burgdorf et al., 2013; Dwyer et al., 2012; Karasawa et al., 2005; Koike et al., 2011; Li et al., 2010; Lu et al., 2015).”
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
“In particular, administration of ketamine [42, 52, 247, 341–344], mGluR2/3 antagonists [196], GluN2B-NMDAR antagonists [42], GLYX-13 [128, 330], scopolamine [85], 7-chlorokynurenic acid [97], and 5-HT2C antagonists [239] induces a fast-onset increase in levels of phospho-mTOR (Ser 2448), phospho-p70S6 kinase (Thr 389)…”
BackgroundLin, J., Huang, L., Yu, J., Xiang, S., Wang, J., Zhang, J., Yan, X., Cui, W., He, S., & Wang, Q. (2016) · Marine Drugs · doi:10.3390/md14040067 · Cited by 142
Self-citationLiu, R.-J., Duman, C., Kato, T., Hare, B., Lopresto, D., Bang, E., Burgdorf, J., Moskal, J., Taylor, J., Aghajanian, G., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.202 · Cited by 105
Yang, B., Zhang, J.-C., Han, M., Yao, W., Yang, C., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4399-2 · Cited by 91
“The doses of R-ketamine (10 mg/kg) and rapastinel (10 mg/kg) were selected as reported previously (Lu et al. 2014; Yang et al. 2015b, 2016; Zhang et al. 2014).”
MethodSelf-citationJiang, C., Lin, W.-J., Labonté, B., Tamminga, C. A., Turecki, G., Nestler, E. J., Russo, S. J., & Salton, S. R. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0277-4 · Cited by 43
Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date
Ragguett, R.-M., Rong, C., Kratiuk, K., & McIntyre, R. S. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1559295 · Cited by 30
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
ERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice
Shen, M., Lv, D., Liu, X., & Wang, C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02290-5 · Cited by 22
Self-citation
Metadata
- Authors
- Lu, Y., Wang, C., Xue, Z., Li, C., Zhang, J., Zhao, X., Liu, A., Wang, Q., & Zhou, W.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03
- Volume
- 18
- Issue
- 5
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2170086392
- Cited by
- 75
- References
- 8
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.